Cabaletta Bio (CABA) Net Income towards Common Stockholders (2018 - 2026)

Cabaletta Bio's Net Income towards Common Stockholders history runs 8 years deep, the most recent figure standing at -$48.5 million for Q4 2025.

• In Q4 2025, Net Income towards Common Stockholders fell 48.2% year-over-year to -$48.5 million; the TTM figure through Dec 2025 stood at -$205.6 million (up 4.1% YoY), while the FY2025 annual figure was -$324.1 million, down 43.49% from the prior year.
• Net Income towards Common Stockholders for Q4 2025 stood at -$48.5 million, up from -$66.9 million in the prior quarter.
• The five-year high for Net Income towards Common Stockholders was -$13.9 million in Q4 2021, with the low at -$94.8 million in Q1 2024.
• The 5-year median for Net Income towards Common Stockholders is -$33.4 million (2023), against an average of -$38.6 million.
• The sharpest annual moves came in 2023 and 2025: Net Income towards Common Stockholders sank 327.09% in 2023, then soared 56.62% in 2025.
• Cabaletta Bio's Net Income towards Common Stockholders stood at -$13.9 million in 2021, then slumped by 33.92% to -$18.6 million in 2022, then decreased by 3.09% to -$19.2 million in 2023, then sank by 70.68% to -$32.7 million in 2024, then slumped by 48.2% to -$48.5 million in 2025.
• Business Quant data shows CABA's Net Income towards Common Stockholders at -$48.5 million in Q4 2025, -$66.9 million in Q3 2025, and -$49.1 million in Q2 2025.